Blockade Therapeutics

Blockade Therapeutics™ is developing a portfolio of innovative MedTech-focused assets that address unmet needs in vascular medicine.

Team

Tyson Brill is the Founder and Managing Partner of Goldilocks Development Partners, a technology-focused venture company developing novel treatments for unmet needs in vascular medicine. He also serves as an Expert Clinic Mentor at MATTER, a global healthcare incubator.
A senior healthcare executive, investor, and advisor, Mr. Brill brings over two decades of leadership and commercial experience in the medical device industry. He has successfully guided multiple early-stage vascular technologies from market introduction through acquisition, including two companies from launch to exit.
His background consists of extensive start-up, sales planning, and business development experience gained through leadership positions and key roles at ArtVentive Medical Group, Infraredx, Inc. (acquired by Nipro Corporation), AccessClosure (acquired by Cardinal Health, Inc.), and GE Healthcare.

Sean Morris is a highly accomplished executive, entrepreneur, and investor with 25 years of experience in the medical device industry.
He currently serves as the CEO of Amplifi Vascular, Inc., showcasing his ongoing involvement in leading innovative medical technology development. Mr. Morris is also a General Partner at Cultivation Capital, applying his operational and exit experience to venture investment.
Throughout his career, he has demonstrated exceptional success in the start-up ecosystem, having been a founder or board member of five companies that have collectively realized three successful exits valued in excess of $270 million.
Key achievements include: Founder and CEO of Veniti (venous stent): Successfully led the company to its acquisition by Boston Scientific (BSCI) in 2018, Founder, Advisor, and Board Member at Euphrates Vascular, Former SVP of Peripheral Vascular at AngioDynamics.